View in EDS HTML Full Text PDF Full Text

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.

Saved in:
Bibliographic Details
Title: Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
Authors: King, Madeleine T., Stockler, Martin R., O’Connell, Rachel L., Buizen, Luke, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Bryce, Jane, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sehouli, Jalid, Feeney, Amanda, Berton-Rigaud, Dominique, Costa, Daniel S. J., Friedlander, Michael L., for the GCIG Symptom Benefit group
Source: Quality of Life Research. Jan2018, Vol. 27 Issue 1, p59-74. 16p.
Subjects: Ovarian cancer treatment, Ovarian cancer diagnosis, Cancer chemotherapy, Health surveys, Palliative treatment, Mental health, Quality of life, Cancer relapse, Comparative studies, Health status indicators, Longitudinal method, Research methodology, Medical cooperation, Ovarian tumors, Questionnaires, Research, Research evaluation, Research funding, Evaluation research
Abstract: Purpose: Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed to review, revise, and validate a patient-reported outcome measure (PROM), the Measure of Ovarian Symptoms and Treatment concerns (MOST), developed in GCIG-SBS Stage 1 (MOSTv1, 35 items), and document recurrent ovarian cancer (ROC) symptom burden and benefit.Methods: GCIG-SBS Stage 2 recruited patients with platinum-resistant/refractory ROC (PRR-ROC) or potentially platinum-sensitive ROC with ≥ 3 lines of prior chemotherapy (PPS-ROC ≥ 3). Patients completed MOSTv1, QLQ-C30, QLQ-OV28, and FACT-O/FOSI at baseline and before cycle 3 of chemotherapy (pre-C3), and global assessments of change (MOST-Change) pre-C3. Clinicians rated patients' cancer-related symptoms, performance status, and adverse events. Convergent and divergent validity (Spearman's correlations), discriminative validity (effect sizes between groups classified by clinician-rated characteristics), and responsiveness (paired t tests in patients expected to experience clinically meaningful change) were assessed.Results: Of 948 recruits, 903 completed PROMs at baseline and 685 pre-C3. Baseline symptom burden was substantial for PRR-ROC and PPS-ROC ≥ 3. MOSTv2 has 24 items and five multi-item scales: abdominal symptoms (MOST-Abdo), disease or treatment-related symptoms (MOST-DorT), chemotherapy-related symptoms (MOST-Chemo), psychological symptoms (MOST-Psych), and MOST-Well-being. Correlations confirmed concurrent and divergent validity. Discriminative validity was confirmed by effect sizes that conformed with a priori hypotheses. MOST-Abdo was responsive to improvements in abdominal symptoms and MOST-Chemo detected the adverse effects of chemotherapy.Conclusions: The MOSTv2 validly quantifies patient-reported symptom burden, adverse effects, and symptom benefit in ROC, and as such is fit-for-purpose for clinical trials of palliative chemotherapy in ROC. Further research is required to assess test-retest reliability. [ABSTRACT FROM AUTHOR]
Copyright of Quality of Life Research is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 127379429
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22King%2C+Madeleine+T%2E%22">King, Madeleine T.</searchLink><br /><searchLink fieldCode="AR" term="%22Stockler%2C+Martin+R%2E%22">Stockler, Martin R.</searchLink><br /><searchLink fieldCode="AR" term="%22O’Connell%2C+Rachel+L%2E%22">O’Connell, Rachel L.</searchLink><br /><searchLink fieldCode="AR" term="%22Buizen%2C+Luke%22">Buizen, Luke</searchLink><br /><searchLink fieldCode="AR" term="%22Joly%2C+Florence%22">Joly, Florence</searchLink><br /><searchLink fieldCode="AR" term="%22Lanceley%2C+Anne%22">Lanceley, Anne</searchLink><br /><searchLink fieldCode="AR" term="%22Hilpert%2C+Felix%22">Hilpert, Felix</searchLink><br /><searchLink fieldCode="AR" term="%22Okamoto%2C+Aikou%22">Okamoto, Aikou</searchLink><br /><searchLink fieldCode="AR" term="%22Aotani%2C+Eriko%22">Aotani, Eriko</searchLink><br /><searchLink fieldCode="AR" term="%22Bryce%2C+Jane%22">Bryce, Jane</searchLink><br /><searchLink fieldCode="AR" term="%22Donnellan%2C+Paul%22">Donnellan, Paul</searchLink><br /><searchLink fieldCode="AR" term="%22Oza%2C+Amit%22">Oza, Amit</searchLink><br /><searchLink fieldCode="AR" term="%22Avall-Lundqvist%2C+Elisabeth%22">Avall-Lundqvist, Elisabeth</searchLink><br /><searchLink fieldCode="AR" term="%22Berek%2C+Jonathan+S%2E%22">Berek, Jonathan S.</searchLink><br /><searchLink fieldCode="AR" term="%22Sehouli%2C+Jalid%22">Sehouli, Jalid</searchLink><br /><searchLink fieldCode="AR" term="%22Feeney%2C+Amanda%22">Feeney, Amanda</searchLink><br /><searchLink fieldCode="AR" term="%22Berton-Rigaud%2C+Dominique%22">Berton-Rigaud, Dominique</searchLink><br /><searchLink fieldCode="AR" term="%22Costa%2C+Daniel+S%2E+J%2E%22">Costa, Daniel S. J.</searchLink><br /><searchLink fieldCode="AR" term="%22Friedlander%2C+Michael+L%2E%22">Friedlander, Michael L.</searchLink><br /><searchLink fieldCode="AR" term="%22for+the+GCIG+Symptom+Benefit+group%22">for the GCIG Symptom Benefit group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Quality+of+Life+Research%22">Quality of Life Research</searchLink>. Jan2018, Vol. 27 Issue 1, p59-74. 16p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Ovarian+cancer+treatment%22">Ovarian cancer treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Ovarian+cancer+diagnosis%22">Ovarian cancer diagnosis</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+chemotherapy%22">Cancer chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Health+surveys%22">Health surveys</searchLink><br /><searchLink fieldCode="DE" term="%22Palliative+treatment%22">Palliative treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Mental+health%22">Mental health</searchLink><br /><searchLink fieldCode="DE" term="%22Quality+of+life%22">Quality of life</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+relapse%22">Cancer relapse</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Health+status+indicators%22">Health status indicators</searchLink><br /><searchLink fieldCode="DE" term="%22Longitudinal+method%22">Longitudinal method</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+cooperation%22">Medical cooperation</searchLink><br /><searchLink fieldCode="DE" term="%22Ovarian+tumors%22">Ovarian tumors</searchLink><br /><searchLink fieldCode="DE" term="%22Questionnaires%22">Questionnaires</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Research+evaluation%22">Research evaluation</searchLink><br /><searchLink fieldCode="DE" term="%22Research+funding%22">Research funding</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Purpose: </bold>Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed to review, revise, and validate a patient-reported outcome measure (PROM), the Measure of Ovarian Symptoms and Treatment concerns (MOST), developed in GCIG-SBS Stage 1 (MOSTv1, 35 items), and document recurrent ovarian cancer (ROC) symptom burden and benefit.<bold>Methods: </bold>GCIG-SBS Stage 2 recruited patients with platinum-resistant/refractory ROC (PRR-ROC) or potentially platinum-sensitive ROC with ≥ 3 lines of prior chemotherapy (PPS-ROC ≥ 3). Patients completed MOSTv1, QLQ-C30, QLQ-OV28, and FACT-O/FOSI at baseline and before cycle 3 of chemotherapy (pre-C3), and global assessments of change (MOST-Change) pre-C3. Clinicians rated patients' cancer-related symptoms, performance status, and adverse events. Convergent and divergent validity (Spearman's correlations), discriminative validity (effect sizes between groups classified by clinician-rated characteristics), and responsiveness (paired t tests in patients expected to experience clinically meaningful change) were assessed.<bold>Results: </bold>Of 948 recruits, 903 completed PROMs at baseline and 685 pre-C3. Baseline symptom burden was substantial for PRR-ROC and PPS-ROC ≥ 3. MOSTv2 has 24 items and five multi-item scales: abdominal symptoms (MOST-Abdo), disease or treatment-related symptoms (MOST-DorT), chemotherapy-related symptoms (MOST-Chemo), psychological symptoms (MOST-Psych), and MOST-Well-being. Correlations confirmed concurrent and divergent validity. Discriminative validity was confirmed by effect sizes that conformed with a priori hypotheses. MOST-Abdo was responsive to improvements in abdominal symptoms and MOST-Chemo detected the adverse effects of chemotherapy.<bold>Conclusions: </bold>The MOSTv2 validly quantifies patient-reported symptom burden, adverse effects, and symptom benefit in ROC, and as such is fit-for-purpose for clinical trials of palliative chemotherapy in ROC. Further research is required to assess test-retest reliability. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Quality of Life Research is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=127379429
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s11136-017-1729-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 16
        StartPage: 59
    Subjects:
      – SubjectFull: Ovarian cancer treatment
        Type: general
      – SubjectFull: Ovarian cancer diagnosis
        Type: general
      – SubjectFull: Cancer chemotherapy
        Type: general
      – SubjectFull: Health surveys
        Type: general
      – SubjectFull: Palliative treatment
        Type: general
      – SubjectFull: Mental health
        Type: general
      – SubjectFull: Quality of life
        Type: general
      – SubjectFull: Cancer relapse
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Health status indicators
        Type: general
      – SubjectFull: Longitudinal method
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Ovarian tumors
        Type: general
      – SubjectFull: Questionnaires
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Research evaluation
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Evaluation research
        Type: general
    Titles:
      – TitleFull: Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: King, Madeleine T.
      – PersonEntity:
          Name:
            NameFull: Stockler, Martin R.
      – PersonEntity:
          Name:
            NameFull: O’Connell, Rachel L.
      – PersonEntity:
          Name:
            NameFull: Buizen, Luke
      – PersonEntity:
          Name:
            NameFull: Joly, Florence
      – PersonEntity:
          Name:
            NameFull: Lanceley, Anne
      – PersonEntity:
          Name:
            NameFull: Hilpert, Felix
      – PersonEntity:
          Name:
            NameFull: Okamoto, Aikou
      – PersonEntity:
          Name:
            NameFull: Aotani, Eriko
      – PersonEntity:
          Name:
            NameFull: Bryce, Jane
      – PersonEntity:
          Name:
            NameFull: Donnellan, Paul
      – PersonEntity:
          Name:
            NameFull: Oza, Amit
      – PersonEntity:
          Name:
            NameFull: Avall-Lundqvist, Elisabeth
      – PersonEntity:
          Name:
            NameFull: Berek, Jonathan S.
      – PersonEntity:
          Name:
            NameFull: Sehouli, Jalid
      – PersonEntity:
          Name:
            NameFull: Feeney, Amanda
      – PersonEntity:
          Name:
            NameFull: Berton-Rigaud, Dominique
      – PersonEntity:
          Name:
            NameFull: Costa, Daniel S. J.
      – PersonEntity:
          Name:
            NameFull: Friedlander, Michael L.
      – PersonEntity:
          Name:
            NameFull: for the GCIG Symptom Benefit group
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan2018
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 09629343
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Quality of Life Research
              Type: main
ResultId 1